{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:47:49Z","timestamp":1792626469784,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.pharma.2022.11.013","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T21:29:40Z","timestamp":1669930180000},"page":"684-695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["\u00c9tude Transversale sur les Effets Ind\u00e9sirables de la Chlorhydrate de M\u00e9tformine chez 130\u00a0Patients Diab\u00e9tiques Type 2\u00a0Admis au Centre M\u00e9dical et \u00e0 la Maison du Diab\u00e8te de Sidi Bel-Abb\u00e8s"],"prefix":"10.1016","volume":"81","author":[{"given":"M.","family":"Sakouhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Matmour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Belakhdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kraroubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2022.11.013_bib0190","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2\u00a0diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharma.2022.11.013_bib0195","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2\u00a0diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharma.2022.11.013_bib0200","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1445-5994.1991.tb01375.x","article-title":"Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus","volume":"21","author":"McIntyre","year":"1991","journal-title":"Aust N Z J Med"},{"issue":"3","key":"10.1016\/j.pharma.2022.11.013_bib0205","first-page":"CD002966","article-title":"Metformin monotherapy for type 2\u00a0diabetes mellitus","volume":"20","author":"Saenz","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharma.2022.11.013_bib0210","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.2337\/dc12-0719","article-title":"Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2\u00a0diabetes and coronary artery disease","volume":"36","author":"Hong","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharma.2022.11.013_bib0215","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2337\/diacare.15.6.755","article-title":"Biguanides and NIDDM","volume":"15","author":"Bailey","year":"1992","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharma.2022.11.013_bib0220","first-page":"59","article-title":"Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss","volume":"38","author":"Ravn","year":"2013","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.pharma.2022.11.013_bib0225","first-page":"1601","article-title":"Activit\u00e9 anticanc\u00e9reuse de la metformine\u00a0: nouvelles perspectives pour une vieille mol\u00e9cule","volume":"6","author":"Beck","year":"2010","journal-title":"Rev Med Suisse"},{"key":"10.1016\/j.pharma.2022.11.013_bib0230","doi-asserted-by":"crossref","first-page":"c2181","DOI":"10.1136\/bmj.c2181","article-title":"Long-term treatment with metformin in patients with type 2\u00a0diabetes and risk of vitamin B-12\u00a0deficiency: randomised placebo-controlled trial","volume":"340","author":"De Jager","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.pharma.2022.11.013_bib0235","series-title":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit (RCP) de la chlorhydrate de m\u00e9tformine","author":"Agence nationale de s\u00e9curit\u00e9 des m\u00e9dicaments","year":"2017"},{"key":"10.1016\/j.pharma.2022.11.013_bib0240","first-page":"664","article-title":"The importance of early haemodiafiltration in the treatment of lactic acidosis associated with the administration of metformin","volume":"32","author":"Bar\u00f3-Serra","year":"2012","journal-title":"Nefrologia"},{"key":"10.1016\/j.pharma.2022.11.013_bib0245","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/dme.12017","article-title":"The criteria for metformin-associated lactic acidosis: the quality of reporting in a large pharmacovigilance database","volume":"30","author":"Kajbaf","year":"2013","journal-title":"Diabet Med"},{"key":"10.1016\/j.pharma.2022.11.013_bib0250","series-title":"International drug monitoring: the role of national centres. Report of WHO Meeting","first-page":"498","author":"Organisation mondiale de la sant\u00e9","year":"2012"},{"issue":"10","key":"10.1016\/j.pharma.2022.11.013_bib0255","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/0003-4819-140-10-200405180-00009","article-title":"Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting","volume":"140","author":"Nebeker","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharma.2022.11.013_bib0260","unstructured":"Statistical Package for the Social Sciences (SPSS) version 20. Disponible sur\u00a0: hps:\/\/spss-64\u00a0bits.fr.softonic.com\/ [Consult\u00e9 le 11\u00a0mars 2017]."},{"key":"10.1016\/j.pharma.2022.11.013_bib0265","first-page":"01","article-title":"DiabCare Alg\u00e9rie","volume":"4","author":"Belhadj","year":"2010","journal-title":"Med Mal Metab"},{"key":"10.1016\/j.pharma.2022.11.013_bib0270","first-page":"08","article-title":"\u00c9tude observationnelle ODYSS\u00c9E\u00a0: dur\u00e9e de maintenance de la bith\u00e9rapie metformine-sitagliptine versus metformine-sulfamides hypoglyc\u00e9miants chez des patients diab\u00e9tiques de type 2","volume":"10","author":"Valensi","year":"2016","journal-title":"Med Mal Metab"},{"key":"10.1016\/j.pharma.2022.11.013_bib0275","first-page":"02","article-title":"Barom\u00e8tre Alg\u00e9rie\u00a0: enqu\u00eate nationale sur la prise en charge des personnes diab\u00e9tiques","volume":"13","author":"Belhadj","year":"2019","journal-title":"Med Mal Metab"},{"key":"10.1016\/j.pharma.2022.11.013_bib0280","first-page":"02","article-title":"Contr\u00f4le glyc\u00e9mique avec insuline glargine\u00a0: \u00e9tude observationnelle men\u00e9e au Maroc aupr\u00e8s de patients diab\u00e9tiques de type 2\u00a0insuffisamment contr\u00f4l\u00e9s par metformine, seule ou en association avec un sulfamide hypoglyc\u00e9miant et\/ou une insuline basale","volume":"11","author":"Latrech","year":"2017","journal-title":"Med Mal Metab"},{"key":"10.1016\/j.pharma.2022.11.013_bib0285","doi-asserted-by":"crossref","first-page":"A75","DOI":"10.1016\/S1262-3636(10)70304-9","article-title":"\u00c9tude de l\u2019influence des caract\u00e9ristiques patients sur la pharmacocin\u00e9tique de la metformine dans un but d\u2019optimisation des sch\u00e9mas posologiques","volume":"36","author":"Nob\u00e9court","year":"2010","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.pharma.2022.11.013_bib0290","doi-asserted-by":"crossref","first-page":"A97","DOI":"10.1016\/S1262-3636(10)70398-0","article-title":"Efficacit\u00e9 et tol\u00e9rance d\u2019une association fixe de fenofibrate et de metformine en co-administration avec un traitement par statine. L\u2019\u00e9tude FAME Metfo","volume":"36","author":"Valensi","year":"2010","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.pharma.2022.11.013_bib0295","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.lpm.2019.09.024","article-title":"Int\u00e9r\u00eat d\u2019une consultation m\u00e9dicale de pharmacovigilance: exemple de la carence en vitamine B12\u00a0avec la metformine","volume":"48","author":"Lafaurie","year":"2019","journal-title":"Presse Med"},{"key":"10.1016\/j.pharma.2022.11.013_bib0300","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40264-020-00913-8","article-title":"Sex diferences in adverse drug reactions of metformin: a longitudinal survey study","volume":"43","author":"De Vries","year":"2020","journal-title":"Drug Safety"},{"issue":"6","key":"10.1016\/j.pharma.2022.11.013_bib0305","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1248\/bpb.35.933","article-title":"The evaluation of risk factors associated with adverse drug reactions by metformin in type 2\u00a0diabetes mellitus","volume":"35","author":"Shinji","year":"2012","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.pharma.2022.11.013_bib0310","series-title":"Bristol-Myers Squibb Company. GLUCOPHAGE\u00ae\/GLUCOPHAGE XR, Response to FDA Comments of 10 12 00. doc\u2013CLEAN DRAFT 10 13 00","first-page":"21","year":"2000"},{"issue":"9","key":"10.1016\/j.pharma.2022.11.013_bib0315","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/FPC.0b013e3283561666","article-title":"Association of genetic variation in the organic cation transporters OCT1, OCT2\u00a0and multidrug and toxin extrusion 1\u00a0transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2\u00a0diabetes patients","volume":"22","author":"Tarasova","year":"2012","journal-title":"Pharmacogenet Genomics"},{"issue":"Suppl. 1","key":"10.1016\/j.pharma.2022.11.013_bib0320","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.2337\/dc14-S081","article-title":"Diagnosis and classification of diabetes mellitus","volume":"37","author":"American Diabetes Association","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharma.2022.11.013_bib0325","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2165\/11536790-000000000-00000","article-title":"Lactic acidosis induced by metformin: incidence, management and prevention","volume":"33","author":"Lalau","year":"2010","journal-title":"Drug Safety"},{"issue":"11","key":"10.1016\/j.pharma.2022.11.013_bib0330","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.2337\/dc08-1171","article-title":"Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis","volume":"31","author":"Michael","year":"2008","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.pharma.2022.11.013_bib0335","first-page":"CD012906","article-title":"Metformin monotherapy for adults with type 2 diabetes mellitus","volume":"6","author":"Gnesin","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.pharma.2022.11.013_bib0340","doi-asserted-by":"crossref","first-page":"446","DOI":"10.5694\/j.1326-5377.2008.tb01713.x","article-title":"Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study","volume":"188","author":"Niklaus","year":"2008","journal-title":"Med J Aust"},{"issue":"2","key":"10.1016\/j.pharma.2022.11.013_bib0345","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2796.2003.01271.x","article-title":"Metformin and lactic acidosis: cause or coincidence? A review of case reports","volume":"255","author":"Stades","year":"2004","journal-title":"J Intern Med"},{"key":"10.1016\/j.pharma.2022.11.013_bib0350","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2050-6511-15-3","article-title":"Rosacea-like facial rash related to metformin administration in a young woman","volume":"15","author":"Laura","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"issue":"8","key":"10.1016\/j.pharma.2022.11.013_bib0355","first-page":"487","article-title":"Vitamin B12\u00a0in type 2\u00a0diabetic patients treated with metformin","volume":"59","author":"Jos\u00e9 Mar\u00eda","year":"2012","journal-title":"Endocrinol Nutr"},{"key":"10.1016\/j.pharma.2022.11.013_bib0360","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2337\/dc11-1582","article-title":"Association of biochemical B12\u00a0deficiency with metformin therapy and vitamin B12\u00a0supplements","volume":"35","author":"Reinstatler","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.pharma.2022.11.013_bib0180","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2337\/dc09-0606","article-title":"Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy","volume":"33","author":"Daryl","year":"2010","journal-title":"Diabetes Care"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922001560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922001560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:38:24Z","timestamp":1757720304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450922001560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0003450922001560"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2022.11.013","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9tude Transversale sur les Effets Ind\u00e9sirables de la Chlorhydrate de M\u00e9tformine chez 130\u00a0Patients Diab\u00e9tiques Type 2\u00a0Admis au Centre M\u00e9dical et \u00e0 la Maison du Diab\u00e8te de Sidi Bel-Abb\u00e8s","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2022.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}